Next-generation fusion specialist SHINE Technologies has secured centralised marketing authorisation (CMA) in Europe for its radioisotope product Ilumira (non-carrier-added lutetium-177), allowing the company to sell Lu-177 across the European Union (EU).

The regulatory clearance enables access to a major market for the use of Lu-177 in targeted radioligand therapies.

The development coincides with several steps by SHINE Technologies to broaden its position in nuclear medicine.